<DOC>
	<DOCNO>NCT00098878</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This randomized phase III trial compare different dos carboplatin see well work treat patient stage IC , stage II , stage III , stage IV ovarian , fallopian tube , primary peritoneal cancer .</brief_summary>
	<brief_title>Carboplatin Treating Patients With Stage IC-IV Ovarian , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare progression-free survival patient stage IC-IV ovarian epithelial , fallopian tube , primary peritoneal cancer treat flat-dose vs intra-patient dose-escalated carboplatin first-line chemotherapy . Secondary - Compare toxic effect regimens patient . - Compare quality life patient treat regimen . - Compare overall clinical response rate CA 125 response patient treat regimen . - Compare overall survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive flat dose carboplatin day 1 . - Arm II : Patients receive intra-patient dose-escalated carboplatin day 1 . In arm , treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Quality life assess baseline , treatment course , 2 month post-chemotherapy . Patients follow every 2 month 2 year , every 3 month 1 year , every 4 month 1 year , every 6 month thereafter . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 1,300 patient ( 650 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial , fallopian tube , primary peritoneal cancer* Stage ICIV disease Peritoneal carcinomatosis* ( ovariantype ) must mucinsecreting tumor Stage IC patient must malignant cell ascitic fluid peritoneal washing , tumor surface ovary , preoperative capsule rupture NOTE : * Histologic confirmation primary source ovary require . If biospy available , cytology show adenocarcinoma allow provide follow criterion meet : Patient pelvis ( ovarian ) mass AND following : Omental cake metastasis large 2 cm upper abdomen and/or regional lymph node metastasis irrespective size OR stage IV disease Serum CA 125/CEA ratio &gt; 25 barium enema ( colonoscopy ) gastroscopy ( radiological examination stomach ) negative presence primary tumor normal mammography within 6 week prior study randomization Initial cytoreductive laparotomy biopsy require within past 8 week Cytoreductive surgery may may successful stag laparotomy No mixed mesodermal tumor No borderline ovarian tumor tumor term `` possibly malignant '' No adenocarcinoma unknown origin , histologically confirm mucinsecreting tumor Considered unsuitable unwilling receive platinumtaxane combination therapy No concurrent endometrial cancer PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 03 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin normal AST ALT ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 5 time ULN Renal Creatinine clearance ≥ 30 mL/min Obstructive hydronephrosis cause borderline ( i.e. , creatinine clearance 3045 mL/min ) renal function must treat study entry Cardiovascular No hypertension No ischemic heart disease No myocardial infarction within past 6 month No congestive heart failure Other Not pregnant nursing Fertile patient must use effective contraception No symptomatic peripheral neuropathy ≥ grade 2 No uncontrolled infection No severe and/or uncontrolled medical condition No malignancy within past 5 year except curatively treat carcinoma situ cervix basal cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy No concurrent cytotoxic chemotherapy progressive disease occur Endocrine therapy Not specify Radiotherapy No prior radiotherapy Surgery See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>